Atossa Therapeutics Inc has recently made an announcement about progress in one of its breast cancer studies.
They’ve completed enrolling participants for a specific part of their Phase 2 clinical trial, known as the I-SPY 2, which is looking into the effectiveness of a treatment called (Z)-endoxifen.
This treatment is being tested as a pre-surgery (neoadjuvant) option for people who have just been diagnosed with a type of breast cancer that responds to estrogen, known as estrogen receptor-positive invasive breast cancer.
In this particular segment of the trial, 20 patients will be given 10 milligrams of (Z)-endoxifen every day for a period of up to 24 weeks before they undergo surgery.
The results of this study, which is a joint effort involving several leading cancer research centers in the United States, Quantum Leap Healthcare, the US Food and Drug Administration, and the Foundation for the National Institutes of Health Cancer Biomarkers Consortium, are expected to be released in the latter half of 2024.
Steven Quay, the CEO of Atossa, highlighted the significance of their work by pointing out that more than 80% of all breast cancer cases are estrogen receptor-positive and that the current pre-surgery treatment options for these patients could be improved. He expressed optimism that Atossa’s (Z)-endoxifen could revolutionize how the hundreds of thousands of women diagnosed with this type of breast cancer every year are treated.
Specifically, he mentioned that this therapy has the potential to make tumors easier to remove surgically, lower the chances of the cancer coming back, and offer safety and tolerability benefits over existing treatments like aromatase inhibitors and systemic chemotherapy.
Atossa is a biopharmaceutical company that is in the clinical stage of developing new treatments for oncology, particularly focusing on breast cancer and addressing areas where current medical treatments do not fully meet patient needs.